Submitted by Anonymous (not verified) on 24 June 2025 - 12:30
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised